Imatinib Mesylate is used to treat chronic myelogenous leukemia, gastrointestinal stromal tumors and a number of other malignancies. It is sold under the brand names Gleevec. Reference standards of Imatinib Mesylate API,and its pharmacopeial, non pharmacopeial impurities, and stable isotopes are listed below.
Imatinib Mesylate
Catalogue No.:PA 09 28000
CAS :
Molecular Formula : C30H35N7O4S
Molecular Weight : 589.71
Imatinib Dimethylamino Impurity
Catalogue No.:PA 09 28010
Molecular Formula : C10H12N2O
Molecular Weight : 176.22
Imatinib Guanidino Impurity
Catalogue No.:PA 09 28020
Molecular Formula : C21H28N6O
Molecular Weight : 380.49
N-Desmethyl Imatinib
Catalogue No.:PA 09 28030
Molecular Formula : C28H29N7O
Molecular Weight : 479.58
Des(methylpiperazinyl) Imatinib Dimer Piperazinium Chloride
Catalogue No.:PA 09 28040
Molecular Formula : C53H51ClN12O2
Molecular Weight : 923.5
Imatinib Diamine Impurity
Catalogue No.:PA 09 28060
Molecular Formula : C16H15N5
Molecular Weight : 277.32
1-Methylpiperazine
Catalogue No.:PA 09 28070
Molecular Formula : C5H12N2
Molecular Weight : 100.16
1-Methylpiperazine Dihydrochloride
Catalogue No.:PA 09 28071
Molecular Formula : C5H14Cl2N2
Molecular Weight : 173.08
1-(Pyridin-3-yl)ethanone
Catalogue No.:PA 09 28080
Molecular Formula : C7H7NO
Molecular Weight : 121.14
Dimethylamine
Catalogue No.:PA 09 28090
Molecular Formula : C2H7N
Molecular Weight : 45.08
Imatinib (Piperidine)-4-oxide
Catalogue No.:PA 09 28100
Molecular Formula : C29H31N7O2
Molecular Weight : 509.60
Desmethylimatinib Mesylate
Catalogue No.:PA 09 0280031
Molecular Formula : C29H33N7O4S
Molecular Weight : 575.69
Imatinib Mesylate - Impurity B (Dihydrochloride)
Catalogue No.:PA 09 0280021
Molecular Formula : C21H30Cl2N6O
Molecular Weight : 453.41
Imatinib Mesylate (IPRSI017)
Catalogue No.:PA IPRSI017
Molecular Formula : NA
Molecular Weight : NA
1-Methylpiperazine 1-oxide
Catalogue No.:PA 09 0281000
Molecular Formula : C5H12N2O
Molecular Weight : 116.16
I accept terms and conditions
Message sent successfully!! We will get back to you shortly ....
